Physician profile
Kyle Parrow
NPI 1033221510
$3,520.25
in general payments reported to CMS, 2019-2025
28 companies · $738 in 2025
The $738 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $441 · 2020: $182 · 2021: $453 · 2022: $422 · 2023: $618 · 2024: $666 · 2025: $738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,923 · Education: $97.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,923.34 |
| Education | $97.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $998.87 | 2022-2025 | |
| Sight Sciences, INC. | $396.78 | 2020-2025 | Omni Surgical System, Sion Surgical Instrument, Tearcare System |
| Mallinckrodt Hospital Products INC. | $347.80 | 2021-2024 | Acthar |
| Alcon Vision LLC | $262.50 | 2019-2025 | Clareon, Eysuvis, Rocklatan |
| Allergan, INC. | $223.33 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $215.44 | 2019-2023 | Cequa |
| Aerie Pharmaceuticals, INC. | $169.73 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $107.99 | 2019-2021 | |
| Glaukos Corporation | $106.00 | 2019-2025 | Idosetr |
| Nova Eye, INC. | $86.88 | 2024 | |
| Oyster Point Pharma, INC. | $81.26 | 2023-2025 | Tyrvaya, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $72.73 | 2019-2021 | |
| Astellas Pharma US INC | $64.70 | 2024 | Izervay |
| Dompe US, INC. | $63.51 | 2019-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $53.73 | 2023-2025 | Vyzulta, Miebo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $37.17 | 2022-2023 | Veritas Vision System |
| Tarsus Pharmaceuticals, INC. | $27.49 | 2025 | Xdemvy |
| New World Medical,INC. | $27.49 | 2024 | Streamline, Kahook Dual Blade, Ahmed Glaucoma Valve |
| Apellis Pharmaceuticals, INC. | $27.08 | 2023 | Syfovre |
| Harrow Eye, LLC | $23.89 | 2024 | Iheezo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $20.55 | 2020 | |
| Shire North American Group INC | $18.68 | 2019 | |
| Horizon Therapeutics Plc | $16.90 | 2023 | Tepezza |
| Biotissue Holdings INC. | $15.79 | 2021 | |
| Eyevance Pharmaceuticals LLC | $15.01 | 2021 | |
| Ocular Therapeutix, INC. | $13.60 | 2021 | |
| Iridex Corporation | $12.82 | 2021 | |
| Omeros Corporation | $12.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Parrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.